We are live on
!
Find out more
AQR Capital Management Portfolio holdings
AUM
$218B
1-Year Est. Return
29.41%
This Fund
S&P 500
This Quarter
Est. Return
-12.77%
1 Year Est. Return
+29.41%
3 Year Est. Return
+92.15%
5 Year Est. Return
+116.61%
10 Year Est. Return
+435.72%
AUM
$44.2B
AUM Growth
-$8.44B
(-16%)
Cap. Flow
-$301M
Cap. Flow
% of AUM
-0.68%
Top 10 Holdings %
Top 10 Hldgs %
14.01%
Holding
2,360
New
150
Increased
1,005
Reduced
998
Closed
187
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$209M |
| 2 |
CVS Health
CVS
|
+$195M |
| 3 |
Tyson Foods
TSN
|
+$136M |
| 4 |
ExxonMobil
XOM
|
+$135M |
| 5 |
LyondellBasell Industries
LYB
|
+$130M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Thermo Fisher Scientific
TMO
|
+$239M |
| 2 |
Microsoft
MSFT
|
+$204M |
| 3 |
Johnson & Johnson
JNJ
|
+$157M |
| 4 |
Amazon
AMZN
|
+$144M |
| 5 |
Walmart Inc
WMT
|
+$137M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 20.23% |
| 2 | Healthcare | 16.49% |
| 3 | Financials | 11.74% |
| 4 | Industrials | 11.47% |
| 5 | Consumer Discretionary | 10.94% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1951
Viavi Solutions
VIAV
$9.18B
| $231K | ﹤0.01% |
+17,477
| New | +$252K |
|
1952
SPX Corp
SPXC
$10.6B
| $230K | ﹤0.01% |
4,354
-7,306
| -63% | -$353K |
|
|
DZSI
1953
DELISTED
DZS Inc. Common Stock
DZSI
| $230K | ﹤0.01% |
14,128
-26,346
| -65% | -$388K |
|
|
BRFS
1954
DELISTED
BRF SA
BRFS
| $229K | ﹤0.01% |
89,438
-2,567
| -3% | -$7.57K |
|
1955
Gulfport Energy Corp
GPOR
$2.97B
| $228K | ﹤0.01% |
2,868
-1,668
| -37% | -$155K |
|
|
BKI
1956
DELISTED
Black Knight, Inc. Common Stock
BKI
| $227K | ﹤0.01% |
3,522
-37,796
| -91% | -$2.54M |
|
1957
Ameris Bancorp
ABCB
$5.88B
| $226K | ﹤0.01% |
+5,613
| New | +$238K |
|
|
ELME
1958
Elme Communities
ELME
$144M
| $225K | ﹤0.01% |
+10,535
| New | +$250K |
|
1959
Harmonic Inc
HLIT
$1.26B
| $224K | ﹤0.01% |
25,821
-17,383
| -40% | -$157K |
|
1960
Supernus Pharmaceuticals
SUPN
$2.74B
| $224K | ﹤0.01% |
+7,746
| New | +$222K |
|
1961
Cheesecake Factory
CAKE
$5.53B
| $223K | ﹤0.01% |
+8,447
| New | +$281K |
|
1962
NACCO Industries
NC
$312M
| $222K | ﹤0.01% |
+5,846
| New | +$279K |
|
1963
eGain
EGAN
$203M
| $221K | ﹤0.01% |
22,678
-33,275
| -59% | -$332K |
|
1964
Enviri
NVRI
$615M
| $221K | ﹤0.01% |
+31,065
| New | +$280K |
|
1965
Brookfield Infrastructure
BIPC
$4.71B
| $220K | ﹤0.01% |
5,188
-2,486
| -32% | -$118K |
|
1966
First Bancorp
FBNC
$2.68B
| $220K | ﹤0.01% |
+6,290
| New | +$235K |
|
1967
Matrix Service
MTRX
$326M
| $220K | ﹤0.01% |
43,424
+31,507
| +264% | +$198K |
|
1968
Red Robin
RRGB
$150M
| $220K | ﹤0.01% |
+27,434
| New | +$296K |
|
1969
Cannae Holdings
CNNE
$644M
| $219K | ﹤0.01% |
11,302
-29,729
| -72% | -$624K |
|
1970
Mercer International
MERC
$34.2M
| $219K | ﹤0.01% |
16,651
+5,135
| +45% | +$76K |
|
1971
Myers Industries
MYE
$1.25B
| $219K | ﹤0.01% |
9,625
-6,941
| -42% | -$157K |
|
1972
Axsome Therapeutics
AXSM
$11.4B
| $218K | ﹤0.01% |
+5,696
| New | +$180K |
|
1973
Coastal Financial
CCB
$743M
| $217K | ﹤0.01% |
5,699
| – | – |
|
1974
Lifecore Biomedical
LFCR
$176M
| $217K | ﹤0.01% |
21,782
-29,093
| -57% | -$288K |
|
|
CCXI
1975
DELISTED
ChemoCentryx, Inc.
CCXI
| $217K | ﹤0.01% |
+8,774
| New | +$193K |
|
Similar funds
VGA
AQR Capital Management's Q2 2022 Portfolio in Review
As of Q2 2022, AQR Capital Management held 2,360 positions worth $44.2B, down 16% from $52.7B the previous quarter. Its ten largest holdings account for 14% of the portfolio.
AQR Capital Management's Q2 2022 filing shows 150 new, 1,005 increased, 998 reduced and 187 closed positions. Its largest new stake was Fluor: 339,891 shares worth $7.86M. The largest sale was Thermo Fisher Scientific, an estimated $239M.
By sector, the portfolio is most concentrated in Technology at 20% of assets, down from 23% a quarter earlier, followed by Healthcare and Financials.
- AQR Capital Management's largest Q2 2022 buy was Fluor: 339,891 shares worth $7.86M.
- AQR Capital Management added most to Gilead Sciences in Q2 2022, an estimated $209M increase.
- AQR Capital Management's biggest Q2 2022 reduction was Thermo Fisher Scientific, cutting an estimated $239M.
- AQR Capital Management fully exited Roku in Q2 2022, selling an estimated $32.5M.
- AQR Capital Management's ten largest holdings make up 14% of its $44.2B portfolio in Q2 2022.
- AQR Capital Management opened 150 new positions and closed 187 in Q2 2022.
- AQR Capital Management's portfolio value fell 16% quarter-over-quarter to $44.2B.
Based on AQR Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.